Yahoo! JAPAN

検索設定 - この検索結果ページについて

Kobashi Haruhiko で検索した結果 1~10件目 / 約25,200件 - 0.37秒

ウェブ

  1. Kobashi - Wiley Online Library
    Professor Haruhiko Kobashi, Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2‐5‐1 Shikata‐cho, Okayama City, Okayama, Japan.
    onlinelibrary.wiley.com/.../j.1440-1746.2008.05593.x
  2. Haruhiko Kobashi's research works | Fukaya Red Cross Hospital ...
    Haruhiko Kobashi's 102 research works with 1586 citations and 1943 reads, including: Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ...
    www.researchgate.net/.../38823870_Haruhiko_Kobashi
  3. KOBASHI Haruhiko - KAKEN — Researchers
    Affiliation (based on the past Project Information):岡山大学,岡山大学病院,講師, Research Field:Gastroenterology, Keywords:肝細胞癌,血管新生,細胞増殖, # of ...
    nrid.nii.ac.jp/nrid/1000000403486/
  4. UMIN-CTR Clinical Trial - UMIN Clinical Trials Registry
    1st name. Middle name. Last name, Haruhiko Kobashi. Organization, Okayama university hospital. Division name ... 1st name. Middle name. Last name, Haruhiko Kobashi. Organization, Okayama university hospital. Division ...
    upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?...
  5. THU-150-Factors associated with treatment failure with SOF+RBV in ...
    THU-150-Factors associated with treatment failure with SOF+RBV in patients with genotype 2 chronic hepatitis C and consideration of retreatment with GLE+PIB in patients not responding to SOF+RBV. Atsunori Kusakabe. x. Atsunori ...
    www.journal-of-hepatology.eu/article/S0618.../abstract
  6. Long-term use of entecavir in nucleoside-naïve Japanese patients ...
    BACKGROUND & AIMS: To evaluate the long-term efficacy of entecavir in nucleoside-naïve chronic hepatitis B patients. METHODS: One hundred and sixty -seven patients treated with entecavir 0.01mg, 0.1mg or 0.5mg for 24-52weeks in  ...
    europepmc.org/abstract/med/20409606
  7. Two cases of development of entecavir resistance ... - Europe PMC
    BACKGROUND: Entecavir (ETV) is a potent nucleoside analogue against hepatitis B virus (HBV), and emergence of drug resistance is rare in nucleoside- naive patients because development of ETV resistance (ETVr) requires at least three ...
    europepmc.org/abstract/med/19669367
  8. Erratum to: Efficacy and resistance of entecavir following 3 years of ...
    Yoshiyasu Karino Email author; Joji Toyota; Hiromitsu Kumada; Yoshiaki Katano; Namiki Izumi; Haruhiko Kobashi; Michio Sata; Mitsuhiko Moriyama; Fumio Imazeki; Masayoshi Kage; Hiroki Ishikawa; Nobuyuki Masaki; Taku ...
    link.springer.com/article/10.1007/s12072-010-9224-0
  9. 肝臓内科 | 岡山赤十字病院
    肝臓内科部長. 小橋 春彦 Haruhiko Kobashi. 昭和59年卒業. 専門領域. 肝臓内科、 消化器内科. 資格. 日本内科学会認定内科医・総合内科専門医・指導医 日本肝臓学会 専門医・指導医 日本消化器内視鏡学会専門医 日本消化器病学会専門医・指導医. 備考.
    www.okayama-med.jrc.or.jp/doctor-info/liver
  10. Two cases of development of entecavir resistance during ... - NCBI
    Haruhiko Kobashi, Shin-ichi Fujioka, [. .... Declaration of Helsinki, Good Clinical Practice guidelines, and Articles/Notifications of the Ministry of Health, Labor and Welfare (H. Kobashi et al., J Gastroenterol Hepatol, in press).
    www.ncbi.nlm.nih.gov/pmc/articles/PMC2716767/
  1  2  3  4  5  6  7  8  9  10  次へ »
検索設定 - この検索結果ページについて

Copyright (C) 2019 Yahoo Japan Corporation. All Rights Reserved.